Amylyx Pharmaceuticals (AMLX) Change in Receivables (2022 - 2025)

Amylyx Pharmaceuticals' Change in Receivables history runs 4 years deep, the most recent figure standing at -$44000.0 for Q4 2025.

• On a quarterly basis, Change in Receivables rose 96.57% year-over-year to -$44000.0 in Q4 2025; TTM through Dec 2025 was -$359000.0, a 99.09% increase from a year earlier, with the FY2025 full-year figure at -$359000.0, up 99.09% from the prior year.
• Change in Receivables slipped to -$44000.0 in Q4 2025 per AMLX's latest filing, from $30000.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $15.9 million in Q2 2023 and bottomed at -$19.7 million in Q1 2024.
• The 4-year median for Change in Receivables is -$147000.0 (2025), against an average of -$3692.3.
• Across the five-year window, Change in Receivables tumbled 975.86% in 2024 and soared 101.27% in 2025, its largest moves.
• Year by year, Change in Receivables stood at $15.2 million in 2022, then decreased by 29.48% to $10.7 million in 2023, then sank by 111.99% to -$1.3 million in 2024, then surged by 96.57% to -$44000.0 in 2025.
• Per Business Quant, the three latest AMLX Change in Receivables figures stand at -$44000.0 (Q4 2025), $30000.0 (Q3 2025), and -$198000.0 (Q2 2025).